OrthoPediatrics (NASDAQ:KIDS – Get Free Report)‘s stock had its “overweight” rating reaffirmed by Piper Sandler in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $45.00 target price on the stock, up from their prior target price of $30.00. Piper Sandler‘s target price would suggest a potential upside of 39.70% from the company’s previous close.
Other equities research analysts have also issued research reports about the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $35.00 target price on shares of OrthoPediatrics in a research note on Wednesday, October 28th. TD Cowen raised their price target on OrthoPediatrics from $23.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, October 28th. Lake Street Capital boosted their price target on OrthoPediatrics from $34.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, October 28th. Truist Financial upped their price objective on OrthoPediatrics from $22.00 to $28.00 and gave the company a “hold” rating in a research report on Wednesday, October 28th. Finally, BTIG Research upped their price objective on OrthoPediatrics from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $33.88.
View Our Latest Research Report on KIDS
OrthoPediatrics Price Performance
KIDS traded up $0.56 during trading on Thursday, reaching $32.21. 10,590 shares of the stock were exchanged, compared to its average volume of 199,582. OrthoPediatrics has a 1 year low of $14.42 and a 1 year high of $34.53. The company has a debt-to-equity ratio of 0.29, a current ratio of 4.55 and a quick ratio of 2.00. The business’s 50 day moving average price is $25.64 and its two-hundred day moving average price is $20.51. The company has a market capitalization of $841.08 million, a price-to-earnings ratio of -22.53 and a beta of 0.90.
OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last posted its earnings results on Tuesday, October 27th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.02). OrthoPediatrics had a negative net margin of 12.83% and a negative return on equity of 8.10%. The business had revenue of $72.66 million for the quarter, compared to analysts’ expectations of $68.50 million. As a group, equities research analysts anticipate that OrthoPediatrics will post -1.09 earnings per share for the current year.
Insiders Place Their Bets
In related news, major shareholder Squadron Capital Llc sold 302,369 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $21.01, for a total value of $6,352,772.69. Following the sale, the insider directly owned 6,201,764 shares of the company’s stock, valued at approximately $130,299,061.64. This trade represents a 4.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Jennifer N. Pritzker sold 302,369 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the completion of the sale, the insider owned 6,201,764 shares of the company’s stock, valued at approximately $130,299,061.64. The trade was a 4.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 2,100,000 shares of company stock valued at $46,747,931. Insiders own 32.50% of the company’s stock.
Institutional Trading of OrthoPediatrics
Institutional investors have recently made changes to their positions in the stock. HighMark Wealth Management LLC purchased a new position in OrthoPediatrics in the third quarter valued at approximately $111,000. Aquatic Capital Management LLC acquired a new stake in OrthoPediatrics in the 3rd quarter valued at $25,000. Goldman Sachs Group Inc. increased its holdings in OrthoPediatrics by 16.5% in the 3rd quarter. Goldman Sachs Group Inc. now owns 354,958 shares of the company’s stock valued at $7,905,000 after purchasing an additional 50,246 shares in the last quarter. Palumbo Wealth Management LLC acquired a new stake in OrthoPediatrics in the 3rd quarter valued at $454,000. Finally, Advisors Asset Management Inc. purchased a new position in OrthoPediatrics in the third quarter valued at about $228,000. 69.05% of the stock is owned by hedge funds and other institutional investors.
OrthoPediatrics Company Profile
OrthoPediatrics Corp. develops and markets orthopedic implants and instruments designed specifically for children and adolescents. Its products support surgeons treating a range of pediatric conditions, including fractures, spinal deformities, limb-length differences and other orthopedic disorders. The company’s portfolio includes systems for trauma and deformity correction, scoliosis treatment, limb lengthening and external fixation, as well as specialized surgical instruments. It also provides related education and support for pediatric orthopedic surgeons and care teams.
Further Reading
- Five stocks we like better than OrthoPediatrics
- Lowe’s Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the Math
- Grounded at 52-Week Lows: When Will Boeing Stock Take Flight?
- Apple’s Next Margin Defense Could Be Hiding in Your Wallet
- From Berlin to Brussels: Tesla’s $3.3 Billion Robotaxi Gamble
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
